# US 2023/0265181 A1 · Single variable domain and antigen binding molecule binding bcma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265181 A1
- Document ID: US20230265181A1
- Status: Published application
- Kind: A1
- Application number: 18/020,584
- Filed: 2021-08-16
- Published: 2023-08-24
- Earliest claimed: 2020-08-20
- Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Applicants: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Inventors: Zipeng ZHEN; Meijuan XIE; Xiuzhen DU; Yimin MA; Bing ZHANG; Tongjie XU; Xiquan ZHANG
- Web page: https://patentgrep.com/patent/US20230265181A1

## CPC

- C07K 16/241: {Tumor Necrosis Factors}
- A61P 35/00: Antineoplastic agents
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An immunoglobulin single variable domain and antigen binding molecule binding BCMA, specifically comprising an immunoglobulin single variable domain and antigen binding molecule, a nucleic acid for encoding the binding molecule, a vector containing the nucleic acid, a cell containing the vector, and a pharmaceutical composition containing the above.

## Claims

### Claim 1

An isolated single variable domain that binds to BCMA, wherein the single variable domain comprises CDR1, CDR2 and CDR3 selected from the group consisting of:
(a) CDR1 having at least 70% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 13, 7 and 16;
(b) CDR2 having at least 85% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 11, 14, 8 and 17; and
(c) CDR3 having at least 85% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 15, 9 and 18.

### Claim 2 (depends on 1)

The isolated single variable domain according to claim 1, wherein the single variable domain comprises CDR1, CDR2 and CDR3 selected from any one of the following:
(ii) CDR1 having at least 70% sequence identity to an amino acid sequence of SEQ ID NO: 10, CDR2 having at least 85% sequence identity to an amino acid sequence of SEQ ID NO: 11, and CDR3 having at least 85% sequence identity to an amino acid sequence of SEQ ID NO: 12;
(iii) CDR1 having at least 70% sequence identity to an amino acid sequence of SEQ ID NO: 13, CDR2 having at least 85% sequence identity to an amino acid sequence of SEQ ID NO: 14, and CDR3 having at least 85% sequence identity to an amino acid sequence of SEQ ID NO: 15;
(i) CDR1 having at least 70% sequence identity to an amino acid sequence of SEQ ID NO: 7, CDR2 having at least 85% sequence identity to an amino acid sequence of SEQ ID NO: 8, and CDR3 having at least 85% sequence identity to an amino acid sequence of SEQ ID NO: 9; and
(iv) CDR1 having at least 70% sequence identity to an amino acid sequence of SEQ ID NO: 16, CDR2 having at least 85% sequence identity to an amino acid sequence of SEQ ID NO: 17, and CDR3 having at least 85% sequence identity to an amino acid sequence of SEQ ID NO: 18.

### Claim 3 (depends on 2)

The isolated single variable domain according to claim 2, wherein the single variable domain comprises CDR1, CDR2 and CDR3 selected from any one of the following:
(ii) CDR1 comprising an amino acid sequence of SEQ ID NO: 10; CDR2 comprising an amino acid sequence of SEQ ID NO: 11; and CDR3 comprising an amino acid sequence of SEQ ID NO: 12;
(iii) CDR1 comprising an amino acid sequence of SEQ ID NO: 13; CDR2 comprising an amino acid sequence of SEQ ID NO: 14; and CDR3 comprising an amino acid sequence of SEQ ID NO: 15;
(i) CDR1 comprising an amino acid sequence of SEQ ID NO: 7; CDR2 comprising an amino acid sequence of SEQ ID NO: 8; and CDR3 comprising an amino acid sequence of SEQ ID NO: 9; and
(iv) CDR1 comprising an amino acid sequence of SEQ ID NO: 16; CDR2 comprising an amino acid sequence of SEQ ID NO: 17; and CDR3 comprising an amino acid sequence of SEQ ID NO: 18.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The isolated single variable domain according to claim 1, wherein the single variable domain comprises an amino acid sequence having at least 85% sequence identity to a sequence of SEQ ID NO: 19, 21, 23 or 25; or the single variable domain comprises an amino acid sequence of SEQ ID NO: 19, 21, 23 or 25.

### Claim 6 (depends on 1)

The isolated single variable domain according to claim 1, wherein the single variable domain is derived from animals of the family Camelidae or is humanized.

### Claim 7 (depends on 1)

The isolated single variable domain according to claim 1, wherein the single variable domain exhibits one of or a combination of several of the following properties:
(i) binding to human BCMA;
(ii) binding to monkey BCMA;
(iii) blocking binding of APRIL to BCMA; or
(iv) not binding to human TACI or/and BAFFR proteins.

### Claim 8 (depends on 1)

An isolated antigen-binding molecule that binds to BCMA and that comprises at least one single variable domain according to claim 1.

### Claim 9 (depends on 8)

The isolated antigen-binding molecule according to claim 8, wherein the antigen-binding molecule is an antibody, a monospecific antibody, a multispecific antibody or an immunoconjugate.

### Claim 10 (depends on 8)

The isolated antigen-binding molecule according to claim 8, exhibiting one of or a combination of several of the following properties:
(i) binding to human BCMA;
(ii) binding to monkey BCMA;
(iii) blocking binding of APRIL to BCMA; and
(iv) not binding to human TACI or/and BAFFR proteins.

### Claim 11 (depends on 8)

A composition comprising an active ingredient and a pharmaceutically acceptable carrier, wherein the active ingredient is the antigen-binding molecule according to claim 8.

### Claim 12

(canceled)

### Claim 13 (depends on 8)

A method for treating a subject with a BCMA-expressing tumor or an autoimmune disease, comprising administering to the subject a therapeutically effective amount of the antigen-binding molecule according to claim 8.

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 6)

The isolated single variable domain according to claim 6, wherein the single variable domain is a VHH.

### Claim 17 (depends on 9)

The isolated antigen-binding molecule according to claim 9, wherein the antibody or the immunoconjugate comprises an immunoglobulin constant region.

### Claim 18 (depends on 17)

The isolated antigen-binding molecule according to claim 17, wherein the immunoglobulin constant region comprises a human immunoglobulin Fc.

### Claim 19 (depends on 18)

The isolated antigen-binding molecule according to claim 18, wherein the Fc is an Fc of IgG1, IgG2, IgG3 or IgG4.

### Claim 20 (depends on 9)

The isolated antigen-binding molecule according to claim 9, wherein the antigen-binding molecule comprises an amino acid sequence set forth in SEQ ID NO: 27, 29, 31 or 33.

### Claim 21 (depends on 13)

The method according to claim 13, wherein the tumor is a B-cell malignancy.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the B-cell malignancy is lymphoma, myeloma, multiple myeloma or leukemia.

### Claim 23 (depends on 13)

The method according to claim 13, wherein the autoimmune disease is systemic lupus erythematosus.
